Motavizumab hit with FDA complete response letter for RSV
This article was originally published in Scrip
Executive Summary
AstraZeneca's biologics business, MedImmune, has received a complete response letter from the US FDAasking for additional information on motavizumab, intended for the prevention of serious respiratory syncytial virus (RSV) disease.